Life Science News

Latest updates from the biotech and pharma world

Endpoints News 2026-02-11

Madrigal pads MASH pipeline with six siRNAs from China's Ribo

Endpoints News 2026-02-11

Gubra forms venture unit; Galecto's $275M offering

Endpoints News 2026-02-11

How a closet full of EKG machines illustrates pharma’s clinical trial cost problem

Endpoints News 2026-02-11

Oscar Health expects explosive growth for 2026, but it comes with a risk

Endpoints News 2026-02-11

Post-Hoc Live: Is biotech’s relationship with the FDA at a breaking point?

Endpoints News 2026-02-11

Upstream Bio says verekitug delivered positive data in Phase 2 severe asthma trial

Endpoints News 2026-02-10

Moderna accuses FDA of shifting standard as agency refuses flu shot review

Endpoints News 2026-02-10

Isomorphic claims major advance with new AI drug design engine

Endpoints News 2026-02-10

ILiAD raises $115M round to advance whooping cough vaccine

Endpoints News 2026-02-10

AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight

Endpoints News 2026-02-10

NIH stops low-dose Xarelto arm of large stroke study due to safety concerns

Endpoints News 2026-02-10

Is AstraZeneca on track to meet its $80B revenue target?

Endpoints News 2026-02-10

The fallout from Novo vs. Hims

Endpoints News 2026-02-10

Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs

Endpoints News 2026-02-10

Nektar posts one-year eczema success; Pfizer ends malnutrition trial

Endpoints News 2026-02-10

CSL’s Paul McKenzie out, as Gordon Naylor named interim CEO

Endpoints News 2026-02-10

AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back

Endpoints News 2026-02-10

'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos

Endpoints News 2026-02-10

Hengrui, Kailera push obesity pill ahead on promising mid-stage China data

Endpoints News 2026-02-09

FDA rejects Regenxbio's Hunter syndrome gene therapy

-341 / 30